Eli Lilly and Co. (LLY) Given a $85.00 Price Target at JPMorgan Chase & Co.
Several other research analysts also recently commented on the company. Morgan Stanley set a $73.00 target price on Eli Lilly and and gave the stock a hold rating in a research note on Thursday. Atlantic Securities downgraded Eli Lilly and from an overweight rating to a neutral rating in a research note on Friday. BMO Capital Markets downgraded Eli Lilly and from an outperform rating to a market perform rating and set a $64.00 target price for the company. in a research note on Wednesday. Citigroup Inc. reissued a buy rating on shares of Eli Lilly and in a research note on Tuesday, November 8th. Finally, Jefferies Group reissued a buy rating and set a $100.00 target price (down previously from $105.00) on shares of Eli Lilly and in a research note on Friday, October 28th. Four analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Eli Lilly and presently has a consensus rating of Buy and a consensus price target of $92.34.
Shares of Eli Lilly and (NYSE:LLY) traded up 1.65% on Thursday, reaching $69.12. 8,620,682 shares of the company’s stock were exchanged. The stock has a market cap of $73.11 billion, a P/E ratio of 30.07 and a beta of 0.28. The company’s 50 day moving average price is $76.69 and its 200-day moving average price is $77.92. Eli Lilly and has a 52-week low of $64.18 and a 52-week high of $88.16.
Eli Lilly and (NYSE:LLY) last issued its earnings results on Tuesday, October 25th. The company reported $0.88 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.96 by $0.08. The business had revenue of $5.19 billion for the quarter, compared to analyst estimates of $4.23 billion. Eli Lilly and had a return on equity of 23.71% and a net margin of 11.73%. The firm’s revenue was up 4.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.89 EPS. Equities analysts forecast that Eli Lilly and will post $3.55 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, December 9th. Shareholders of record on Tuesday, November 15th will be issued a dividend of $0.51 per share. This represents a $2.04 dividend on an annualized basis and a dividend yield of 2.95%. The ex-dividend date is Thursday, November 10th. Eli Lilly and’s payout ratio is 88.70%.
In other Eli Lilly and news, insider Maria A. Crowe sold 2,248 shares of the stock in a transaction that occurred on Wednesday, October 5th. The stock was sold at an average price of $81.37, for a total transaction of $182,919.76. Following the transaction, the insider now directly owns 94,319 shares in the company, valued at approximately $7,674,737.03. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.20% of the company’s stock.
Several institutional investors have recently bought and sold shares of LLY. Vanguard Group Inc. boosted its position in Eli Lilly and by 2.2% in the second quarter. Vanguard Group Inc. now owns 63,236,677 shares of the company’s stock worth $4,979,889,000 after buying an additional 1,350,329 shares during the last quarter. Franklin Resources Inc. boosted its position in Eli Lilly and by 2.5% in the second quarter. Franklin Resources Inc. now owns 28,430,876 shares of the company’s stock worth $2,238,939,000 after buying an additional 685,898 shares during the last quarter. BlackRock Institutional Trust Company N.A. boosted its position in Eli Lilly and by 1.1% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 26,674,046 shares of the company’s stock worth $2,100,581,000 after buying an additional 289,681 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Eli Lilly and by 3.0% in the second quarter. JPMorgan Chase & Co. now owns 23,184,616 shares of the company’s stock worth $1,825,790,000 after buying an additional 668,184 shares during the last quarter. Finally, BlackRock Fund Advisors boosted its position in Eli Lilly and by 2.5% in the third quarter. BlackRock Fund Advisors now owns 17,629,570 shares of the company’s stock worth $1,414,949,000 after buying an additional 423,179 shares during the last quarter. Hedge funds and other institutional investors own 75.11% of the company’s stock.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Stock Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related stocks with our FREE daily email newsletter.